<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00267046</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0511</org_study_id>
    <nct_id>NCT00267046</nct_id>
  </id_info>
  <brief_title>Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma</brief_title>
  <official_title>A Phase II Study to Evaluate the Pharmacokinetics, Safety, and Obtain a Preliminary Efficacy Assessment of Palifermin in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary:

        1. To evaluate the preliminary efficacy of palifermin in reducing the incidence and
           severity of oral mucositis (OM) in patients with sarcoma receiving multicycle
           chemotherapy.

        2. To evaluate the pharmacokinetics (PK) of palifermin when given pre chemotherapy.

        3. To evaluate the safety profile of palifermin when combined with multicycle chemotherapy.

      Exploratory:

        1. To evaluate the biologic effect of palifermin on oral mucosa.

        2. To investigate potential biomarker development by biochemical analysis in blood cells,
           serum, and plasma.

        3. To investigate the effects of genetic variation in mucositis genes, drug metabolism
           genes, and drug target genes on patient response to the treatment regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Palifermin is similar to a protein keratinocyte growth factor (KGF) that is naturally made in
      your body in small amounts. The function of palifermin is to stimulate the growth of specific
      cells that form the tissue lining of your mouth and digestive tract. Damage to these cells
      results in the breakdown of the normal protective barrier that these cells usually provide,
      potentially resulting in infection.

      If you are eligible to take part in this study, you will be randomly assigned (as in the toss
      of a coin) to receive either palifermin or placebo by vein 3 days before each cycle of
      chemotherapy. This will be done for 18 weeks (a total of 12 injections). A placebo is a
      substance that looks like the study drug, but which has no active ingredients. The infusion
      time will last 15-30 seconds. At the beginning of the study, for every 3 patients who are
      enrolled on this study, 2 of the 3 will receive palifermin. Neither you nor the study doctor
      will know which study drug you are assigned to receive.

      Within 1 or 2 days before you receive your first dose of palifermin and between 48 to 72
      hours after you receive your first dose of palifermin, additional non-invasive optical
      imaging procedures may be performed. The purpose of these imaging procedures is to evaluate
      the effects of palifermin on mucosa (mucosal thickness). The types of optical imaging that
      may be done include optical coherence tomography (OCT), fluorescence and reflectance
      spectroscopy, or confocal microscopy. The oral cavity will be inspected and photographed. A
      probe about the size of a pen will be placed on one or two sites of oral buccal mucosa. A
      beam of light will then be directed to the oral tissue and optical signals will be collected
      from each site. This will take about 1 minute for each site. Before using the probe for each
      new participant, it will be disinfected per standard practice.

      You will receive adriamycin with ifosfamide or cisplatin chemotherapy. Adriamycin will be
      given as a continuous infusion through your central venous catheter (CVC) for 3 days.
      Ifosfamide will be given intravenously (intravenously (IV)--through a needle in your vein)
      through your CVC over 3 hours, every day for 4 days. Mesna will be given as a 24-hour IV
      infusion through your CVC every day for 4 days through the same catheter. Mesna is used to
      protect against bladder-related side effects. For patients with certain types of sarcoma,
      vincristine will be given through the catheter by rapid infusion on Day 1 only. In patients
      with bone sarcoma, cisplatin will be given on the first day as IV or intra-arterial infusion
      over around 4 hours instead of ifosfamide.

      You will need to come in to M. D. Anderson every 3 weeks for about 4 to 5 months during the
      treatment period, unless your doctor decides you need to come in more frequently. At these
      visits, you will have your vital signs measured and routine blood tests (about 3 teaspoons
      each) will be performed. In addition, you may have your oral cavity examined and photographed
      before and after receiving the study drug. Every effort will be made to take photographs in
      which you cannot be identified.

      Additional blood samples (about 3 teaspoons) will be taken before each cycle and as
      frequently as needed to measure your blood count and other tests to monitor the drug side
      effects and treatment effects. By the end of the study, you will have given about 10
      tablespoons of blood. This amount includes the optional blood draws should you choose to
      allow it to be drawn.

      You will be responsible for notifying study staff (at your doctors visits or over the phone
      with the study staff) of any side effects you experience or medications (over the counter or
      prescription) that you take during the treatment period. You will also be required to notify
      any other doctors (separate from the study doctors) you see that you are participating in
      this research study.

      If your anemia becomes severe while you are on study, then a transfusion may be recommended.
      If mucositis develops, the prohibited medicines can be allowed for treatment of the
      condition. If you experience an intolerable side effect while on study, you may be taken off
      study. If you leave the study early for any reason, your doctor will continue to follow your
      progress for 4 weeks and will access your medical records for a minimum of 1 year after the
      last dose of study drug (either palifermin or placebo) was given.

      At your end of study visit, you will be evaluated for your disease status with imaging
      studies [computed tomography (CT) scans or magnetic resonance images (MRI)] and your weight
      and vitals signs will be measured. You will report any medications you have taken since your
      last visit and any side effects or blood transfusion that you have had. You will also have a
      final blood draw (about 3 teaspoons) for routine tests.

      The total length of your involvement in this study is expected to be about 18 weeks (4 to 5
      months).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Incidence Rate of Oral Mucositis</measure>
    <time_frame>Within 6 blinded cycles (3-week cycles), up to 18 weeks.</time_frame>
    <description>Cumulative incidence of World Health Organization (WHO) grade 2 or &gt; mucositis (moderate to severe) in participants completing up to 6 blinded cycles. Rate defined as participants who had Grade 2 or &gt; divided by total number of participants who completed up to 6 blinded cycles.
WHO Criteria of Grade 1: possible buccal mucosal scalloping with/without erythema; No ulcers; swallows solid diet. Grade 2: ulcers with or without erythema; swallow solid diet. Grade 3: ulcers with/without (extensive) erythema; swallow liquid, not solid diet. Grade 4: mucositis to extent alimentation not possible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Maximum Score for Patient Reported Outcomes in 2 Blinded Cycles</measure>
    <time_frame>Within the first 2 blinded cycles (3-week cycles), up to 6 weeks.</time_frame>
    <description>Median maximum score (0 to 10, with 10 being the worst) for participant-reported outcomes in the first 2 blinded cycles for Mouth Pain, Overall Mouth and Throat Soreness, and Rectal Soreness while median maximum score for Swallowing, Drinking and Eating Difficulty (0 to 4, with 4 being the difficult).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Sarcoma</condition>
  <condition>Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>Palifermin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palifermin + Chemotherapy (Adriamycin (Doxorubicin)+ Ifosfamide (AI) or Adriamycin (Doxorubicin) + Cisplatin (AP) Regimen); Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.
AP=Doxorubicin (Adriamycin) + Cisplatin:
Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Chemotherapy (AI or AP Regimen);
AI = Doxorubicin (Adriamycin) + Ifosfamide:
A single dose placebo prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.
AP=Doxorubicin (Adriamycin) + Cisplatin:
A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palifermin</intervention_name>
    <description>180 mcg/kg 3 days prior to chemotherapy</description>
    <arm_group_label>Palifermin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose 3 days prior to chemotherapy</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin (Doxorubicin)</intervention_name>
    <description>30 mg/m^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m^2).</description>
    <arm_group_label>Palifermin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>2.5 g/m^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m^2); for patients receiving the AI Regimen.</description>
    <arm_group_label>Palifermin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.</description>
    <arm_group_label>Palifermin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>120 mg/m^2 on day 0, for patients receiving the AP Regimen.</description>
    <arm_group_label>Palifermin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>CDDP</other_name>
    <other_name>Platinol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with sarcoma which is locally advanced, at high risk for relapse or
             metastatic for whom treatment with high dose doxorubicin (90 mg/m2) with ifosfamide
             (AI) or cisplatinum (AP) is indicated.

          2. Patients (male and female) with childbearing potential (defined as not post-menopausal
             for 12 months, negative blood pregnancy test, or no previous surgical sterilization)
             must use adequate birth control.

          3. Adequate hematologic (Absolute neutrophil count (ANC)&gt;/= 1500/mm^3, &gt;/= Hgb 10gm/dL,
             platelet count &gt;/= 150,000/mm^3), renal (serum creatinine &lt;/= 1.5mg/dL), hepatic
             (serum bilirubin count &lt;/= 1.5 * normal and SGPT &lt; 3 * normal) functions.

          4. Karnofsky Performance Status &gt;/= 80.

          5. Signed informed consent form.

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Patients with comorbid condition which renders patients at high risk of treatment
             complication.

          3. Patients with metastatic disease to CNS.

          4. Patient has uncontrolled angina, congestive heart failure (New York Heart Association
             &gt; class II or known ejection fraction &lt; 40%), uncontrolled cardiac arrhythmia, acute
             myocardial infarction within 3 months or has uncontrolled hypertension.

          5. Patient has an active seizure disorder. Patients with a previous history of seizure
             disorders will be eligible for the study, if they have had no evidence of seizure
             activity, and they have been free of antiseizure medication for the previous 5 years.

          6. Prior surgery or radiotherapy (RT) within 2 weeks of study entry.

          7. Prior treatment with palifermin, or other keratinocyte growth factors (eg, KGF-2).

          8. Thirty days or less since receiving an investigational product or device in another
             clinical trial. Current enrollment in another clinical trial is not permitted unless
             the sole purpose of the trial is to obtain post-treatment data on the subject (eg,
             long-term follow-up or survival data).

          9. Known sensitivity to any of the products to be administered during this study,
             including Escherichia coli-derived products.

         10. Psychological, social, familial, or geographical reasons that would prevent scheduled
             visits and follow-up.

         11. Patients with a history of pancreatitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saroj Vadhan-Raj, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas MDAnderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center</description>
  </link>
  <results_reference>
    <citation>Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig JA, O'Roark S, Gillenwater AM, Bueso-Ramos C, El-Naggar AK, Benjamin RS. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med. 2010 Sep 21;153(6):358-67. doi: 10.7326/0003-4819-153-6-201009210-00003.</citation>
    <PMID>20855800</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2005</study_first_submitted>
  <study_first_submitted_qc>December 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2005</study_first_posted>
  <results_first_submitted>January 18, 2012</results_first_submitted>
  <results_first_submitted_qc>April 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2012</results_first_posted>
  <last_update_submitted>April 17, 2012</last_update_submitted>
  <last_update_submitted_qc>April 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoma</keyword>
  <keyword>Soft Tissue Sarcoma</keyword>
  <keyword>Oral Mucositis</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Adriamycin</keyword>
  <keyword>Ifosfamide</keyword>
  <keyword>Palifermin</keyword>
  <keyword>Vincristine</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 12/2005 to 02/2008. All recruitment done at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 49 enrolled, one participant withdrew before assignment to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Palifermin</title>
          <description>Palifermin + Chemotherapy (AI or AP Regimen);
AI = Doxorubicin (Adriamycin) + Ifosfamide:
Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.
AP=Doxorubicin (Adriamycin) + Cisplatin:
Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo + Chemotherapy (AI or AP Regimen):
AI = Doxorubicin (Adriamycin) + Ifosfamide:
A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.
AP=Doxorubicin (Adriamycin) + Cisplatin:
A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Chemotoxicity</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Open-label palifermin</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Radiation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Palifermin</title>
          <description>Palifermin + Chemotherapy (AI or AP Regimen);
AI = Doxorubicin (Adriamycin) + Ifosfamide:
Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.
AP=Doxorubicin (Adriamycin) + Cisplatin:
Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo + Chemotherapy (AI or AP Regimen):
AI = Doxorubicin (Adriamycin) + Ifosfamide:
A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.
AP=Doxorubicin (Adriamycin) + Cisplatin:
A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="17" upper_limit="63"/>
                    <measurement group_id="B2" value="39" lower_limit="15" upper_limit="64"/>
                    <measurement group_id="B3" value="42" lower_limit="15" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants on two different chemotherapy regimens.</title>
          <description>Number of participants on two different chemotherapy regimens:AI; AP.</description>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Number of participants on AI chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants on AP chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants' Completion of 6 Blinded Cycles</title>
          <description>Number of participants completing six (6) blinded treatment cycles; one cycle equals 3 weeks.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Completed 6 Cycles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Completed 6 Cycles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Incidence Rate of Oral Mucositis</title>
        <description>Cumulative incidence of World Health Organization (WHO) grade 2 or &gt; mucositis (moderate to severe) in participants completing up to 6 blinded cycles. Rate defined as participants who had Grade 2 or &gt; divided by total number of participants who completed up to 6 blinded cycles.
WHO Criteria of Grade 1: possible buccal mucosal scalloping with/without erythema; No ulcers; swallows solid diet. Grade 2: ulcers with or without erythema; swallow solid diet. Grade 3: ulcers with/without (extensive) erythema; swallow liquid, not solid diet. Grade 4: mucositis to extent alimentation not possible.</description>
        <time_frame>Within 6 blinded cycles (3-week cycles), up to 18 weeks.</time_frame>
        <population>Intention to treat (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>Palifermin</title>
            <description>Palifermin + Chemotherapy (AI or AP Regimen);
AI = Doxorubicin (Adriamycin) + Ifosfamide:
Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.
AP=Doxorubicin (Adriamycin) + Cisplatin:
Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo + Chemotherapy (AI or AP Regimen):
AI = Doxorubicin (Adriamycin) + Ifosfamide:
A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.
AP=Doxorubicin (Adriamycin) + Cisplatin:
A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence Rate of Oral Mucositis</title>
          <description>Cumulative incidence of World Health Organization (WHO) grade 2 or &gt; mucositis (moderate to severe) in participants completing up to 6 blinded cycles. Rate defined as participants who had Grade 2 or &gt; divided by total number of participants who completed up to 6 blinded cycles.
WHO Criteria of Grade 1: possible buccal mucosal scalloping with/without erythema; No ulcers; swallows solid diet. Grade 2: ulcers with or without erythema; swallow solid diet. Grade 3: ulcers with/without (extensive) erythema; swallow liquid, not solid diet. Grade 4: mucositis to extent alimentation not possible.</description>
          <population>Intention to treat (ITT).</population>
          <units>Percentage of Participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cumulative incidence of WHO grade 2 or higher muco</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="24" upper_limit="62"/>
                    <measurement group_id="O2" value="88" lower_limit="52" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative Incidence of WHO Grade 3 or 4 Mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="4" upper_limit="27"/>
                    <measurement group_id="O2" value="51" lower_limit="23" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fine and Gray method.</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Maximum Score for Patient Reported Outcomes in 2 Blinded Cycles</title>
        <description>Median maximum score (0 to 10, with 10 being the worst) for participant-reported outcomes in the first 2 blinded cycles for Mouth Pain, Overall Mouth and Throat Soreness, and Rectal Soreness while median maximum score for Swallowing, Drinking and Eating Difficulty (0 to 4, with 4 being the difficult).</description>
        <time_frame>Within the first 2 blinded cycles (3-week cycles), up to 6 weeks.</time_frame>
        <population>Intention to treat (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>Palifermin</title>
            <description>Palifermin + Chemotherapy (AI or AP Regimen);
AI = Doxorubicin (Adriamycin) + Ifosfamide:
Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.
AP=Doxorubicin (Adriamycin) + Cisplatin:
Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo + Chemotherapy (AI or AP Regimen):
AI = Doxorubicin (Adriamycin) + Ifosfamide:
A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.
AP=Doxorubicin (Adriamycin) + Cisplatin:
A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Maximum Score for Patient Reported Outcomes in 2 Blinded Cycles</title>
          <description>Median maximum score (0 to 10, with 10 being the worst) for participant-reported outcomes in the first 2 blinded cycles for Mouth Pain, Overall Mouth and Throat Soreness, and Rectal Soreness while median maximum score for Swallowing, Drinking and Eating Difficulty (0 to 4, with 4 being the difficult).</description>
          <population>Intention to treat (ITT).</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mouth Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Mouth and Throat Soreness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="5.5" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal Soreness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinking Difficulty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating Difficulty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swallowing Difficulty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years and 3 months.</time_frame>
      <desc>Adverse events reported were found in the first two blinded cycles.</desc>
      <group_list>
        <group group_id="E1">
          <title>Palifermin</title>
          <description>Palifermin + Chemotherapy (AI or AP Regimen);
AI = Doxorubicin (Adriamycin) + Ifosfamide:
Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.
AP=Doxorubicin (Adriamycin) + Cisplatin:
Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo + Chemotherapy (AI or AP Regimen):
AI = Doxorubicin (Adriamycin) + Ifosfamide:
A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.
AP=Doxorubicin (Adriamycin) + Cisplatin:
A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increased thickness of oral mucosa</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Altered taste</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Film coating in mouth</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Increased sensitivity in tongue or gums</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Warm sensation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Increased saliva</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Saroj Vadhan-Raj, MD/Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-7966</phone>
      <email>xzhou@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

